Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ628630,50,16
KB768771-0,77
PKN78,478,48-3,54
Msft-0,56
Nokia4,3364,3515-0,90
IBM-1,70
Daimler AG76,9877,01-3,00
PFE-1,70
19.06.2021 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 18.06.2021
Edwards Lifesci (EW, NY Consolidated)
Závěr k 18.6.2021 Změna (%) Změna (USD) Objem obchodů (ks)
100,71 -0,28 -0,28 3 222 641
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 19.06.2021
Popis společnosti
Obecné informace
Název společnostiEdwards Lifesciences Corp
TickerEW
Kmenové akcie:Ordinary Shares
RICEW
ISIN-
Poslední známé roční výsledky31.12.2020
Poslední známé čtvrtletní výsledky31.03.2021
Počet zaměstnanců k 31.12.2020 14 900
Akcie v oběhu k 23.04.2021 621 636 777
MěnaUSD
Konstituent indexůS&P 500
Kontaktní informace
Ulice1 Edwards Way
MěstoIRVINE
PSČ92614-5688
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon19 492 502 500
Fax13026555049

Business Summary: Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care. It also develops hemodynamic monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. It is developing products, such as the Edwards SAPIEN 3 Ultra System and Edwards SAPIEN XT transcatheter heart valve, among others. Its Transcatheter Heart Valve Therapy and Surgical Heart Valve Therapy products are manufactured in the United States, Singapore and Switzerland. Critical Care products are manufactured in its facilities located in Puerto Rico and the Dominican Republic.
Financial Summary: BRIEF: For the three months ended 31 March 2021, EdwardsLifesciences Corp revenues increased 8% to $1.22B. Netincome increased 9% to $338.2M. Revenues reflectTranscatheter Aortic Valve Replacement segment increase of7% to $791.7M, Surgical Heart Valve Therapy segmentincrease of 10% to $213M, Critical Care segment increase of7% to $195.6M, Europe segment increase of 13% to $280M,Rest of the world segment increase of 24% to $129.6M.
Odvětvová klasifikace
TRBC2009Advanced Medical Equipment
TRBC2012Advanced Medical Equipment & Technology (NEC)
RBSS2004Advanced Medical Equipment
MGINDUSTRYMedical Equipment & Supplies
MGSECTORHealthcare
NAICS2007Electromedical Apparatus Mfg
NAICS2007Surgical Appliance & Supplies Mfg
NAICS1997Electromedical and Electrotherapeutic Apparatus Manufacturing
NAICS1997Surgical Appliance and Supplies Manufacturing
SICSurgical Appliances And Supplies
SICElectromedical Equipment
SICSurgical Appliances And Supplies



  • Poslední aktualizace: 19.06.2021
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, Chief Executive OfficerMichael Mussallem6803.04.200003.04.2000
Chief Financial Officer, Corporate Vice PresidentScott Ullem5402.01.201402.01.2014
Corporate Vice President - EMEA (Europe, Middle East and Africa)Jean-Luc Lemercier63
Corporate Vice President - Strategy and Corporate DevelopmentDonald Bobo59
Corporate Vice President - Surgical Structural HeartDaveen Chopra42
Corporate Vice President - Critical CareCatherine Szyman54
Corporate Vice President - Japan, Asia and PacificHuimin Wang6403.04.2000
Corporate Vice President - Transcatheter Aortic Valve ReplacementLarry Wood5501.01.2007